The Program for Drug Development in Leukemia (PDD-L) offers patients the most advanced treatments available for acute leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and chronic myeloid leukemia through participation in phase 1 clinical trials. Within this program, we concentrate on trials with novel therapeutics and new mechanisms of action coupled with translational research that support future scientific discoveries.
In the PDD-L our goal is to:
- Improve the survival and quality of life of patients with leukemias and related diseases
- Rapidly translate preclinical science into novel treatments for patients
- Build an effective drug development program that excels in data collection, regulatory compliance, and rapid study activation.
To make an appointment or refer a patient, please call 646-608-3749.
If you would like further information about the Program for Drug Development in Leukemia, please contact: